A supplemental application against NDA 213871 — Pfizer's abrocitinib, marketed as Cibinqo — was recorded in the FDA's Drugs@FDA database on 2 September 2026. Abrocitinib is an oral selective JAK1 inhibitor licensed for moderate-to-severe atopic dermatitis in adults and adolescents whose disease is not adequately controlled by other systemic therapies.
What the entry does not say is what the supplement covers. Supplements span a wide range: a manufacturing change, a labelling revision, a new dosage form, a paediatric extension, an efficacy supplement adding an indication. The database record carries the application number, the sponsor and the active ingredient, and nothing further. Reporting it as a new indication would be an invention.
The practical point for prescribers is unchanged today. Abrocitinib carries the class boxed warning shared by JAK inhibitors — serious infection, mortality, malignancy, major adverse cardiovascular events and thrombosis — and the pre-treatment work-up and monitoring that go with it. If you are already prescribing it, keep checking the current prescribing information rather than relying on a database entry; if a change to the label has been made, that is where it will appear. What CDSCO has or has not done with this molecule is not addressed by an FDA record.
- Check the current US prescribing information directly before assuming any labelling change.
- Screen for tuberculosis, viral hepatitis and baseline lipids and counts before starting any JAK inhibitor.
- Take a cardiovascular and thrombotic risk history, and a malignancy history, before prescribing.
- Do not describe a supplement as an approval for a new use when counselling a patient.
Why it matters
A supplement is often mistaken for an expanded licence, and prescribing follows the mistake.
Don't overread it
A supplemental application is administrative — it is not evidence of a new indication or a new safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free